Clinical Trial: Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC
Study Status: Completed
Recruit Status: RECRUITING
Condition: Head and Neck Squamous Cell Carcinoma
Study Type: INTERVENTIONAL
Official Title: A Phase 2 Study of Preoperative Pembrolizumab and Chemotherapy Followed by Adjuvant Pembrolizumab in Resectable Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma
Brief Summary:
This research study is evaluating effectiveness and safety of a combination of immunotherapy drug, pembrolizumab, with chemotherapy, as a possible treatment before and after surgery for squamous cell carcinoma of the head and neck (HNSCC).The combination of pembrolizumab and chemotherapy will be given prior to your surgery, while immunotherapy pembrolizumab will be continued for approximately 1 year after surgery.The names of the study drugs involved in this research study are:pembrolizumab (a type of…
Read more